With a market cap of $234.7 billion, Amgen Inc. (AMGN) is a leading biotechnology company that discovers, develops, manufactures, and delivers innovative medicines to address some of the world’s most challenging diseases. With more than 45 years of industry experience, the company leverages biology, advanced technology, and human genetic data to develop treatments across a broad range of areas, including cancer, heart disease, inflammatory conditions, rare diseases, and obesity.
The Thousand Oaks, California-based company is expected to release its fiscal Q3 2026 results after the market closes on Tuesday, Nov. 3. Ahead of this event, analysts expect AMGN to report an adjusted EPS of $5.72, up 1.4% from $5.64 in the prior year's quarter. It has surpassed Wall Street's bottom-line estimates in the past four quarters.